BR112014000965B8 - Método, aparelho e meio de armazenamento não transitório - Google Patents

Método, aparelho e meio de armazenamento não transitório

Info

Publication number
BR112014000965B8
BR112014000965B8 BR112014000965A BR112014000965A BR112014000965B8 BR 112014000965 B8 BR112014000965 B8 BR 112014000965B8 BR 112014000965 A BR112014000965 A BR 112014000965A BR 112014000965 A BR112014000965 A BR 112014000965A BR 112014000965 B8 BR112014000965 B8 BR 112014000965B8
Authority
BR
Brazil
Prior art keywords
methods
trainer
appliance
tissue
storage media
Prior art date
Application number
BR112014000965A
Other languages
English (en)
Other versions
BR112014000965B1 (pt
BR112014000965A2 (pt
Inventor
Franciscus Johannes Verhaegh Wilhelmus
Van De Stolpe Anja
Jan Van Ooijen Hendrik
Chakravarthi Dulla Kalyana
Alves De India Marcia
Hoffmann Ralf
Original Assignee
Koninklijke Philips Nv
Innosign B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninklijke Philips Nv, Innosign B V filed Critical Koninklijke Philips Nv
Publication of BR112014000965A2 publication Critical patent/BR112014000965A2/pt
Publication of BR112014000965B1 publication Critical patent/BR112014000965B1/pt
Publication of BR112014000965B8 publication Critical patent/BR112014000965B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N5/00—Computing arrangements using knowledge-based models
    • G06N5/04—Inference or reasoning models
    • G06N5/048—Fuzzy inferencing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/20—Probabilistic models
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Molecular Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Data Mining & Analysis (AREA)
  • Immunology (AREA)
  • Software Systems (AREA)
  • General Engineering & Computer Science (AREA)
  • Evolutionary Computation (AREA)
  • Artificial Intelligence (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Pathology (AREA)
  • Probability & Statistics with Applications (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mathematical Physics (AREA)

Abstract

MÉTODO, E APARELHO. O presente pedido de patente principalmente refere-se a métodos específicos para inferir a atividade de uma ou mais via(s) de sinalização celular no tecido de um indivíduo sob avaliação médica, pelo menos com base no(s) nível(is) de expressão de um ou mais gene(s)-alvo da(s) via(s) de sinalização celular medido(s) em uma amostra extraída do tecido do material médico, um aparelho compreendendo um compressor digital configurado para realizar tais métodos e um meio de armazenamento não-transitório armazenando instruções que são executáveis por um dispositivo de processamento digital para realizar tais métodos.
BR112014000965A 2011-07-19 2012-07-19 Método, aparelho e meio de armazenamento não transitório BR112014000965B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161509137P 2011-07-19 2011-07-19
US61/509,137 2011-07-19
EP11178148.0 2011-08-19
EP11178148A EP2549399A1 (en) 2011-07-19 2011-08-19 Assessment of Wnt pathway activity using probabilistic modeling of target gene expression
PCT/IB2012/053686 WO2013011479A2 (en) 2011-07-19 2012-07-19 Assessment of cellular signaling pathway activity using probabilistic modeling of target gene expression

Publications (3)

Publication Number Publication Date
BR112014000965A2 BR112014000965A2 (pt) 2017-06-13
BR112014000965B1 BR112014000965B1 (pt) 2021-08-24
BR112014000965B8 true BR112014000965B8 (pt) 2022-11-08

Family

ID=44582424

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014000965A BR112014000965B8 (pt) 2011-07-19 2012-07-19 Método, aparelho e meio de armazenamento não transitório

Country Status (12)

Country Link
US (2) US11443831B2 (pt)
EP (6) EP2549399A1 (pt)
JP (3) JP6204354B2 (pt)
KR (1) KR102064004B1 (pt)
CN (2) CN103649337B (pt)
BR (1) BR112014000965B8 (pt)
DK (3) DK3418396T3 (pt)
ES (3) ES2700617T3 (pt)
IN (1) IN2014CN00675A (pt)
MX (1) MX352827B (pt)
RU (1) RU2719194C2 (pt)
WO (1) WO2013011479A2 (pt)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
EP2549399A1 (en) 2011-07-19 2013-01-23 Koninklijke Philips Electronics N.V. Assessment of Wnt pathway activity using probabilistic modeling of target gene expression
ES2797533T3 (es) 2012-02-28 2020-12-02 Novartis Ag Selección de pacientes con cáncer para la administración de inhibidores de la señalización Wnt utilizando el estado mutacional de Rnf43
EP2882445B1 (en) 2012-08-13 2019-04-24 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
JP6449779B2 (ja) * 2012-12-26 2019-01-09 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 目的遺伝子発現の線形結合を用いた細胞信号伝達経路活性の評価
TWI582239B (zh) * 2013-03-11 2017-05-11 諾華公司 與ｗｎｔ抑制劑相關之標記
US11309059B2 (en) 2013-04-26 2022-04-19 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signalling pathway activities
JP6054555B2 (ja) * 2013-06-28 2016-12-27 ナントミクス，エルエルシー 診断テストを特定するための経路分析
EP3052933B1 (en) * 2013-10-02 2019-09-04 Suri Technologies Ltd. Patient-specific immunotherapy for treating heterogeneous tumors
CA2923092C (en) 2014-01-03 2019-12-17 Koninklijke Philips N.V. Assessment of the pi3k cellular signaling pathway activity using mathematical modelling of target gene expression
US9880257B2 (en) * 2014-09-11 2018-01-30 Google Llc Gaussian process-based approach for identifying correlation between wireless signals
US9838847B2 (en) 2014-09-11 2017-12-05 Google LLP Data driven evaluation and rejection of trained Gaussian process-based wireless mean and standard deviation models
US9810762B2 (en) * 2014-09-11 2017-11-07 Google Inc. Calculating mean wireless signal strengths using a gaussian process approach incorporating predictive standard deviations
JP6730983B2 (ja) 2014-09-19 2020-07-29 ザ プロボスト，フェローズ，ファウンデーション スカラーズ，アンド ジ アザー メンバーズ オブ ボード，オブ ザ カレッジ オブ ザ ホーリー アンド アンディブ．トリニティー オブ クイーン エリザベス，ニアー ダブリン 癌の再発リスクを予測する方法
US11357799B2 (en) 2014-10-03 2022-06-14 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
US10016159B2 (en) 2014-10-24 2018-07-10 Koninklijke Philips N.V. Determination of TGF-β pathway activity using unique combination of target genes
CA2965408C (en) * 2014-10-24 2023-10-24 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
AU2015334841B2 (en) * 2014-10-24 2022-02-03 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
CN105760707B (zh) * 2014-12-18 2018-07-31 中国科学院大连化学物理研究所 细胞基因翻译过程建模方法
BR112018002848A2 (pt) 2015-08-14 2018-11-06 Koninklijke Philips Nv método, aparelho, mídia de armazenamento não transitório, programa de computador, kit para medir níveis de expressão de seis ou mais genes-alvo da via de sinalização celular
EP3341875A1 (en) * 2015-08-27 2018-07-04 Koninklijke Philips N.V. An integrated method and system for identifying functional patient-specific somatic aberations using multi-omic cancer profiles
CN106897578B (zh) * 2015-12-15 2020-02-14 中国科学院大连化学物理研究所 一种细胞基因翻译过程建模方法
WO2017123662A1 (en) 2016-01-11 2017-07-20 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
US20170329914A1 (en) * 2016-05-11 2017-11-16 International Business Machines Corporation Predicting Personalized Cancer Metastasis Routes, Biological Mediators of Metastasis and Metastasis Blocking Therapies
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
US10621236B2 (en) * 2016-09-16 2020-04-14 At&T Intellectual Property I, L.P. Concept based querying of graph databases
WO2018057542A1 (en) 2016-09-20 2018-03-29 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
US11990209B2 (en) 2016-11-11 2024-05-21 University of Pittsburgh—Of the Commonwealth System of Higher Educat Identification of instance-specific somatic genome alterations with functional impact
CN110382521B (zh) 2016-11-25 2024-07-05 皇家飞利浦有限公司 从氧化应激区分肿瘤抑制性foxo活性的方法
CN106755464A (zh) * 2017-01-11 2017-05-31 上海易毕恩基因科技有限公司 用于筛选肠癌和/或胃癌的基因标志物的方法、用该方法筛选的基因标志物及其用途
CN108300783A (zh) * 2017-01-11 2018-07-20 上海易毕恩基因科技有限公司 用于筛选肠癌和/或胃癌的基因标志物的方法、用该方法筛选的基因标志物及其用途
JP7336769B2 (ja) 2017-04-19 2023-09-01 シーダーズ―シナイ メディカル センター 骨格筋ジストロフィーを治療する方法及び組成物
CN107184991B (zh) * 2017-05-03 2020-05-26 武汉爱博泰克生物科技有限公司 PRDM15基因序列在制备NF-κB抑制剂中的应用
CN107164508A (zh) * 2017-06-16 2017-09-15 上海易毕恩基因科技有限公司 用于检测肝癌的基因标志物及其用途
EP3431582A1 (en) 2017-07-18 2019-01-23 Koninklijke Philips N.V. Cell culturing materials
CN107201411A (zh) * 2017-07-27 2017-09-26 上海市长宁区妇幼保健院 Mylk基因作为诊断子宫内膜癌的标志物
CN107385051A (zh) * 2017-08-04 2017-11-24 上海易毕恩生物技术有限公司 用于检测肝肿瘤良恶性的基因标志物、试剂盒及检测方法
EP3462348A1 (en) 2017-09-28 2019-04-03 Koninklijke Philips N.V. Bayesian inference
EP3462349A1 (en) * 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of notch cellular signaling pathway activity using mathematical modelling of target gene expression
EP3461916A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat3 cellular signaling pathway activity using mathematical modelling of target gene expression
CA3077501A1 (en) 2017-10-02 2019-04-11 Koninklijke Philips N.V. Determining functional status of immune cells types and immune response
EP3461915A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3502279A1 (en) * 2017-12-20 2019-06-26 Koninklijke Philips N.V. Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3727351A4 (en) 2017-12-20 2021-10-06 Cedars-Sinai Medical Center MODIFIED EXTRACELLULAR VESICLES FOR IMPROVED TISSUE DELIVERY
US11475995B2 (en) * 2018-05-07 2022-10-18 Perthera, Inc. Integration of multi-omic data into a single scoring model for input into a treatment recommendation ranking
CN113626397A (zh) * 2018-06-16 2021-11-09 王梅 对数据文件进行动态处理的方法及系统
US11354591B2 (en) 2018-10-11 2022-06-07 International Business Machines Corporation Identifying gene signatures and corresponding biological pathways based on an automatically curated genomic database
WO2020124585A1 (zh) * 2018-12-21 2020-06-25 北京哲源科技有限责任公司 获得细胞内确定性事件的方法、电子设备及存储介质
JP7386897B2 (ja) 2019-05-03 2023-11-27 コーニンクレッカ フィリップス エヌ ヴェ 高悪性度漿液性卵巣癌における予後予測の方法
EP3812474A1 (en) 2019-10-22 2021-04-28 Koninklijke Philips N.V. Methods of prognosis in high-grade serous ovarian cancer
JP2022532161A (ja) * 2019-05-08 2022-07-13 シーダーズ―シナイ メディカル センター 治療活性細胞およびエクソソーム
EP3739588A1 (en) 2019-05-13 2020-11-18 Koninklijke Philips N.V. Assessment of multiple signaling pathway activity score in airway epithelial cells to predict airway epithelial abnormality and airway cancer risk
EP4013866A4 (en) 2019-08-16 2023-08-30 Tempus Labs, Inc. SYSTEMS AND METHODS FOR DETECTING CELL PATHWAY DISORDER IN CANCER SAMPLES
EP3822368A1 (en) 2019-11-14 2021-05-19 Koninklijke Philips N.V. Assessment of pr cellular signaling pathway activity using mathematical modelling of target gene expression
EP3835433A1 (en) 2019-12-12 2021-06-16 Koninklijke Philips N.V. Notch signaling pathway activity as prognostic marker in bladder cancer
US20210209478A1 (en) 2019-12-12 2021-07-08 Tempus Labs, Inc. Real-World Evidence of Diagnostic Testing and Treatment Patterns in U.S. Breast Cancer Patients with Implications for Treatment Biomarkers from RNA-Sequencing Data
CN111139300B (zh) * 2020-02-19 2021-08-17 伯克利南京医学研究有限责任公司 一组结肠癌预后相关基因的应用
EP3882363A1 (en) 2020-03-17 2021-09-22 Koninklijke Philips N.V. Prognostic pathways for high risk sepsis patients
EP3978628A1 (en) 2020-10-01 2022-04-06 Koninklijke Philips N.V. Prognostic pathways for viral infections
WO2021209567A1 (en) 2020-04-16 2021-10-21 Koninklijke Philips N.V. Prognostic pathways for viral infections
CN111739586B (zh) * 2020-06-17 2024-04-05 浙江大学 以87个基因作为生物标志物预测细胞增殖活性的模型
EP3940704A1 (en) 2020-07-14 2022-01-19 Koninklijke Philips N.V. Method for determining the differentiation state of a stem cell
EP3960875A1 (en) 2020-08-28 2022-03-02 Koninklijke Philips N.V. Pcr method and kit for determining pathway activity
EP3965119A1 (en) 2020-09-04 2022-03-09 Koninklijke Philips N.V. Methods for estimating heterogeneity of a tumour based on values for two or more genome mutation and/or gene expression related parameter, as well as corresponding devices
EP3974540A1 (en) 2020-09-25 2022-03-30 Koninklijke Philips N.V. Method for predicting immunotherapy resistance
EP4015651A1 (en) 2020-12-17 2022-06-22 Koninklijke Philips N.V. Treatment prediction and effectiveness of anti-tnf alpha treatment in ibd patients
EP4039825A1 (en) 2021-02-09 2022-08-10 Koninklijke Philips N.V. Comparison and standardization of cell and tissue culture
WO2022189530A1 (en) 2021-03-11 2022-09-15 Koninklijke Philips N.V. Prognostic pathways for high risk sepsis patients
CN113278700B (zh) * 2021-06-04 2022-08-09 浙江省肿瘤医院 一种用于乳腺癌分型及预后预测的引物组及试剂盒
WO2023084039A1 (en) * 2021-11-15 2023-05-19 Innosign B.V. Assessment of gr cellular signaling pathway activity using mathematical modelling of target gene expression
CN113963745A (zh) * 2021-12-07 2022-01-21 国际竹藤中心 一种构建植物发育分子调控网络的方法及其应用
WO2024033063A1 (en) 2022-08-12 2024-02-15 Innosign B.V. Prediction and monitoring of immunotherapy in cancer
CN116083590B (zh) * 2023-03-23 2024-03-22 雄安妙心医学检验有限公司 一种基因检测试剂盒及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566130B1 (en) * 2000-01-28 2003-05-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Androgen-regulated gene expressed in prostate tissue
US7371736B2 (en) * 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
EP1380644A1 (en) 2002-07-08 2004-01-14 Kylix B.V. The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role
AU2003260973A1 (en) * 2002-09-05 2004-03-29 Toolgen, Inc. Bioinformatics analysis of cellular effects of artificial transcription factors
US20070009923A1 (en) * 2005-01-24 2007-01-11 Massachusetts Institute Of Technology Use of bayesian networks for modeling cell signaling systems
CA2608359A1 (en) 2005-05-13 2006-11-23 Duke University Gene expression signatures for oncogenic pathway deregulation
JP2009521736A (ja) 2005-11-07 2009-06-04 スキャンスカウト，インコーポレイテッド リッチメディアと共に広告をレンダリングするための技術
CA2651929A1 (en) * 2006-05-17 2007-11-29 Timothy S. Gardner Method to determine transcriptional regulation pathways in organisms
WO2008086182A2 (en) * 2007-01-04 2008-07-17 University Of Rochester Use of gene signatures to design novel cancer treatment regimens
JP2010178650A (ja) 2009-02-04 2010-08-19 Univ Of Tokyo 固形癌の再発予測のための試験方法および再発予防剤
US20120252689A1 (en) 2011-04-01 2012-10-04 Zhong Wu Gene expression signature for wnt/b-catenin signaling pathway and use thereof
JP2014513959A (ja) * 2011-05-05 2014-06-19 クリニカル ジェノミクス ピーティーワイ リミテッド 新生物の診断方法
EP2549399A1 (en) 2011-07-19 2013-01-23 Koninklijke Philips Electronics N.V. Assessment of Wnt pathway activity using probabilistic modeling of target gene expression

Also Published As

Publication number Publication date
DK3173489T3 (en) 2018-12-10
EP3173489B1 (en) 2018-09-19
EP3418396B1 (en) 2021-03-24
KR102064004B1 (ko) 2020-01-08
JP6807430B2 (ja) 2021-01-06
EP3831957A1 (en) 2021-06-09
EP2549399A1 (en) 2013-01-23
CN109852671A (zh) 2019-06-07
BR112014000965B1 (pt) 2021-08-24
EP3418396A1 (en) 2018-12-26
MX2014000557A (es) 2014-05-01
ES2700617T3 (es) 2019-02-18
JP2014520566A (ja) 2014-08-25
EP3831957B1 (en) 2022-09-07
DK2734643T3 (en) 2017-03-20
US11443831B2 (en) 2022-09-13
DK3418396T3 (da) 2021-05-25
EP4130291A1 (en) 2023-02-08
EP2734643A2 (en) 2014-05-28
CN103649337B (zh) 2018-11-13
RU2014106026A (ru) 2015-08-27
JP6783729B2 (ja) 2020-11-11
JP2017205129A (ja) 2017-11-24
EP4130291C0 (en) 2024-01-10
RU2719194C2 (ru) 2020-04-17
KR20140046464A (ko) 2014-04-18
IN2014CN00675A (pt) 2015-04-03
WO2013011479A2 (en) 2013-01-24
US20140156200A1 (en) 2014-06-05
EP2734643B1 (en) 2016-12-07
JP2019129850A (ja) 2019-08-08
EP3173489A1 (en) 2017-05-31
ES2874452T3 (es) 2021-11-05
US20230105263A1 (en) 2023-04-06
JP6204354B2 (ja) 2017-09-27
ES2617195T3 (es) 2017-06-15
CN103649337A (zh) 2014-03-19
MX352827B (es) 2017-12-11
BR112014000965A2 (pt) 2017-06-13
EP4130291B1 (en) 2024-01-10
WO2013011479A3 (en) 2013-03-14

Similar Documents

Publication Publication Date Title
BR112014000965B8 (pt) Método, aparelho e meio de armazenamento não transitório
BR112015015131A2 (pt) método, aparelho, mídia de armazenamento não transitório, programa de computador, e produto
BR112017007965A2 (pt) método implantado por computador para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; aparelho para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; meio de armazenamento não transitório; programa de computador; kits para medir níveis de expressão de três ou mais genes-alvo da via de sinalização celular de tgf-b em uma amostra de um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; e uso do kit
BR112016003868A2 (pt) método, aparelho, mídia de armazenamento não transitório, e, programa de computador
BR112018002848A2 (pt) método, aparelho, mídia de armazenamento não transitório, programa de computador, kit para medir níveis de expressão de seis ou mais genes-alvo da via de sinalização celular
BR112018069849A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático precoce ou de lesão precursora do câncer pancreático
SA517390218B1 (ar) جهاز وطرق لتحديد النسيج التالف باستخدام قياسات الرطوبة تحت الجلد
EA201891292A1 (ru) Мультиспецифические антитела
WO2016015058A3 (en) Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same
MX2016016902A (es) Metodos para analizar acidos nucleicos de celulas individuales o poblaciones de celulas.
BR112018010933A2 (pt) anticorpos multiespecíficos
GB2519906A (en) Methods and systems for detecting biological components
BR112015018213A2 (pt) método para determinar a síndrome da angústia respiratória aguda (ards) relacionada aos biomarcadores, um método para monitorar o desenvolvimento e o tratamento da ards em um paciente
NZ621733A (en) Lung cancer biomarkers and uses thereof
MY187050A (en) Cancer cell-specific antibody, anticancer agent, and cancer testing method
BR112013001410A2 (pt) aparelhos biossensores e métodos dos mesmos
EA201691682A1 (ru) Способы анализирования редких циркулирующих в крови клеток
MX2022003399A (es) Metodo basado en celulas para determinar la potencia de la defibrotida.
BR112016002709A2 (pt) queratinas como biomarcadores para câncer cervical e sobrevivência
BR112017003167A2 (pt) método in vitro e aparelho para análise do comportamento de substâncias em ambiente fisiológico simulado
WO2014198670A3 (en) Methods of viewing and analyzing high content biological data
CO7151536A2 (es) Bioensayos con calidad controlada basados en células para productos nutricéuticos y medicinales
AR101088A1 (es) Caracterización biológica de un producto farmacológico derivado de acetato de glatiramer mediante células de mamífero humano y no humano
MX357018B (es) Método de diagnóstico temprano de carcinoma hepatocelular.
TW201613622A (en) Composition for skincare and pharmaceutical composition and preparation method thereof

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/07/2012, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: INNOSIGN B.V. (NL)